The safety of CRISPR-Cas9 gene editing is being debated
A study shows problems, but they are surmountable
A GREAT deal rides on the accuracy of the gene-editing tool known as CRISPR-Cas9. Since its discovery in 2012 it has become popular for tinkering with genomes of all kinds, thanks to its ability to make editing cheap and easy. Firms such as CRISPR Therapeutics, Intellia Therapeutics and Editas Medicine have been built on the idea that it could be used to develop treatments for human diseases. Editas, based in Cambridge, Massachusetts, announced this year that it would work on five new human medicines over the next five years.
In China the technology is already in clinical use. In Hangzhou Cancer Hospital, for example, CRISPR-Cas9 is being employed to engineer immune-system cells removed from patients with cancer of the oesophagus. The hope is that when the engineered cells are returned to a patient’s body, the editing will have improved their ability to attack tumours. More studies involving human beings are expected in other countries for the treatment of beta-thalassaemia, a blood disorder, and Leber’s congenital amaurosis, a form of blindness. Further ahead, there is hope that CRISPR-Cas9 will help treat diseases such as AIDS, cystic fibrosis, Huntington’s chorea and Duchenne muscular dystrophy.
This article appeared in the Science & technology section of the print edition under the headline "Cutting to the truth"
Science & technology July 21st 2018
More from Science & technology
It is dangerously easy to hack the world’s phones
A system at the heart of global telecommunications is woefully insecure
The Great Barrier Reef is seeing unprecedented coral bleaching
Continued global warming will mean its obliteration
Some corals are better at handling the heat
Scientists are helping them breed